Because of its pivotal role in cancer genesis and maintenance, the EGFR/RAS/RAF/MEK/ERK signaling cascade has been the subject of intensive research and pharmaceutical scrutiny to identify effective target‐based therapy for cancer treatment (Dhillon et al., 2007; Roberts and Der, 2007; Samatar and Poulikakos, 2014). Here, RAF1 is linked to cancer.